Last talk of Plenary III comes from @KYTsaiLab, titled "Topical MEK Inhibition as Precision Targeted Chemoprevention". Like the 1st talk by @CarolynLeeMDPhD, this talk is focused on cutaneous squamous cell carcinoma 1/n #SID2021
In prior work (nature.com/articles/ncomm…) this group found that MEK inhibition could help prevent progression of lesions from premalignant actinic keratosis to cutaneous SCC #sid2021 2/n
They use a hairless mouse UV-driven cutaneous SCC model for preclinical testing, and found that systemic MEK inhibition prevented skin cancer lesions. To avoid systemic side effects thought, they developed a topical MEK inhibitor gel #sid2021 3/n
Topical MEK inhibition showed a dose dependent response, effectively reducing the development of new tumors without any systemic side effects. This was a local effect, as demonstrated by a study where gel was only applied to one side #sid2021 4/n
Mechanistically, topical MEKi appears to reduce pERK in the skin, as one would expect. The applications of this include cutaneous neurofibromas (clinical trial ongoing) and chemoprevention in high risk SCC patients (clinic trial planned) #sid2021 5/n
An excellent talk all around. Question after the talk is if they have tried this for other tumors. Current neurofibromatosis is the focus - but it hasn't been tested in other cutaneous tumors yet. #sid2021 6/6
• • •
Missing some Tweet in this thread? You can try to
force a refresh
